Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Major efficacy of trabectedin in 2 metastatic osteosarcoma patients with wild-type Asp1104 ERCC5 tumor status.

Onkologie - 1 Jan 2013

Gastaud Lauris, Saâda-Bouzid Esma, Le Morvan Valérie, Pourquier Philippe, Ianessi Antoine, Thariat Juliette, Italiano Antoine, Thyss Antoine

Abstract excerpt

BACKGROUND: Treatment of osteosarcoma of the extremities consists of surgical resection preceded and followed by chemotherapy, including high-dose methotrexate or adriamycin-based protocols. When distant relapse occurs, therapeutic options are scarce. Trabectedin, a DNA-binding agent, is indicated for the treatment of patients with advanced soft tissue sarcomas after failure of anthracyclines and ifosfamide. In...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Bone Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dioxoles

Share to Endonucleases

Share to Genetic Markers

Share to Nuclear Proteins

Share to Osteosarcoma

Share to Treatment Outcome

Source

Identifiers

PMID: 24192772
DOI: 10.1159/000355664

Genes

ERCC5
ERCC1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Major efficacy of trabectedin in 2 metastatic osteosarcoma patients with wild-type Asp1104 ERCC5 tumor status.PMID 24192772Read ↗

ERCC5/XPG, ERCC1, and BRCA1 gene status and clinical benefit of trabectedin in patients with soft tissue sarcoma.Semantic proximity Read ↗

Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: A retrospective multicentric studySemantic proximity Read ↗

Prospective assessment of the predictive value of the BRCA1 gene status in sarcoma patients treated with trabectedin: an updated analysis of the EORTC 62091 trial.Semantic proximity Read ↗

Identification of New Potential Prognostic and Predictive Markers in High-Grade Osteosarcoma Using Whole Exome Sequencing.Semantic proximity Read ↗

Genome sequencing analysis of blood cells identifies germline haplotypes strongly associated with drug resistance in osteosarcoma patientsSemantic proximity Read ↗

BRCA1 haplotype and clinical benefit of trabectedin in soft-tissue sarcoma patients.Semantic proximity Read ↗

Association of four ERCC1 and ERCC2 SNPs with survival of bone tumour patients.Semantic proximity Read ↗

Individualized chemotherapy for osteosarcoma and identification of gene mutations in osteosarcoma.Semantic proximity Read ↗

Cisplatin Resistance in Osteosarcoma: In vitro Validation of Candidate DNA Repair-Related Therapeutic Targets and Drugs for Tailored TreatmentsSemantic proximity Read ↗

Activity of trabectedin and the PARP inhibitor rucaparib in soft-tissue sarcomasSemantic proximity Read ↗

Influence of ERCC2 gene polymorphisms on the treatment outcome of osteosarcoma.Semantic proximity Read ↗

Phase II trial of bevacizumab and satraplatin in docetaxel-pretreated metastatic castrate-resistant prostate cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.